Dupixent Gets A Yes For COPD From The CHMP

 
• By Elizabeth Cairns
  
Generate a summary of this article
Listen to this article
Beta

Sanofi and Regeneron could have the first biologic on the market for COPD – and a potentially better one is in the works.    

Lungs icon, anatomy, health care concept
• Source: Shutterstock

Even as it stumbles in the US in its journey to become the first-ever targeted therapy for COPD, Dupixent (dupilumab) has taken a step closer to Europe. Today the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) gave its imprimatur to Sanofi and Regeneron Pharmaceuticals, Inc.’s anti-inflammatory juggernaut for the lung disease, and approval could come swiftly.

Key Takeaways

  • The European Committee for Medicinal Products for Human Use has granted a positive opinion to Dupixent in COPD as the FDA pushes back its decision.

The CHMP said that Dupixent could be used as an add-on treatment for uncontrolled COPD patients with high levels of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

Scrip-NewProducts (Premium-2): Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again

 
• By Nabil

The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.

Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval

 
• By Dexter Jie Yan

The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Small But Mitey: Tarsus To Amp Up Strong Xdemvy Launch

 
• By Alexandra Shimmings

Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.    

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.